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ABSTRACT 
Triphala, a simple combination of Amalaki, Haritaki and Bibhitaki, have proven 
antioxidant and immunomodulatory activities. But, work on Chaturthamalaka Rasayana, 
containing Triphala, under four alternate combinations, was not found reported yet. For 
this, a study was conducted to evaluate the effect of different four combinations under 
Chaturthamalaka Rasayana on leucocytes and immunoglobulin with special reference to 
immunomodulatory activity in albino wistar rat model. Four combinations of test drugs 
were prepared as per classical textual guidelines mentioned in Charaka Samhita. 36 
wistar strain albino rats were used in the study. Immunosuppression done by 
Cyclophosphamide which induced neutropenia. Total leucocyte count (TLC) (cells/mm3), 
% Neutrophil count and Serum immunoglobulin level (in ZST units) were parameters 
used to evaluate. All the data were collected and analysed using paired‘t’ test and one way 
ANOVA test, followed by Dunnett’s multiple comparison ‘t’ test. All the test formulations 
showed much better effect in comparison with the improvement noted in control group, 
as a cytoprotective agent. However, with respect to immunostimulation, the control group 
showed better effect in comparison to the test formulation. Chaturthamalaka Rasayana 
possesses significant cytoprotective activity and moderate immunostimulant activity. 
Among the four combinations, all test samples were found effective in 
immunosuppressive rats. Test sample IV containing Amalaki, Haritaki and Bibhitaki found 
more potent than or as similar as response in comparison of standard group 
(Levamisole). Chaturthamalaka Rasayana might be consider as a cost effective and 
adulteration free alternative formulation over used of costly Chyavanaprasha Avaleha. 
KEYWORDS: Immunomodulation, Rasayana, Chaturthamalaka, Ayurveda, Triphala. 
INTRODUCTION 
From many decades, after successful 
laboratory research work, the whole world came to 
know about herbs to possess immunomodulatory 
properties. This action is done by stimulating both 
specific and nonspecific immunity. Many herbs used 
in Indian traditional system of medicine were 
reported to have immunomodulation activities. Some 
of these stimulate both humoral and cell mediated 
immunity while other activate only the cellular 
components of the immune system, i.e. phagocytic 
function without affecting the humoral or cell 
mediated immunity. 
In Ayurveda, many traditional formulations 
are described as ‘Rasayana’ have various 
pharmacological properties such as immuno-
modulation, tonic, neurostimulant, antiaging, 
antibacterial, antiviral, anticancer, adoptogenic, 
antistress etc. An entire section of Materia Medica of 
Ayurveda is devoted to drugs entitled as ‘Rasayana’ 
used for improvement of body resistance. Rasayana 
Chikitsa prevents the effects of early ageing develops 
intelligence and increase the body resistance against 
disease. In Charaka Samhita, there are many 
formulations under chapter Rasayana Chikista 
Adhyaya. Within this, after Chyavanprasha Avaleha,[1] 
Chaturthamalaka Rasayana[2] is described as a 
classical immunity booster formulation, beneficial to 
maintain immunity of an individuals. Now a days, 
Chyavanprasha Avaleha is the most popular Ayurveda 
formulation to the worldwide, which has too many 
numbers of contents, which are not easily available, 
may be in the form of adulterant due to Churna 
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(powder) form and also costly. As compared to that, 
Chaturthamalaka Rasayana has basic three main 
herbal ingredients in the form of fresh fruits of 
Amalaki, Haritaki and Bibhitaki with some another 
contents which are easily available. The Phalashruti 
(classical textual results) of Chaturthamalaka 
Rasayana explains the best Rasayana Karma which 
can be ultimately correlated with immunomodulation 
activity.[3] 
On the base of the immunity status, recently, 
cancer has found as the leading cause of death in 
economically developed and the second leading cause 
of death in developed countries, among the non-
communicable diseases.[4] For cancer, chemotherapy 
is the primary treatment available for disseminated 
malignant disease which acts by killing the cells that 
divides rapidly. This means chemotherapy also 
harms the cells that divide rapidly under normal 
circumstances in bone marrow.[5] That’s why it 
ultimately results in to immunosuppression which is 
the major drawback of chemotherapy and also has 
the toxic side effects.[6] Cyclophosphamide is one of 
the most widely used broad spectrum antitumor 
agent, used in the treatment of cancer. 
Cyclophosphamide itself is a carcinogenic, lowers the 
body’s ability to fight an infection causing 
Immunosuppression and also have side effects like 
bone marrow toxicity.[7] Hence in this study, 
Cyclophophamide is used as an immunosuppression 
agent in the animal model to validate the Rasayana 
effect. This is an attempt made to evaluate whether 
the four combinations of Amalaki, Haritaki and 
Bibhitaki under Chaturthamalaka Rasayana has the 
significant immunomodulatory action or not, also it 
was never been studied yet before. That’s why, the 
present study designed to evaluate the effect of 
Chaturthamalaka Rasayana on leucocytes and 
immunoglobulin with special reference to 
immunomodulatory activity in albino wistar rat 
model. 
MATERIALS AND METHODS 
Test formulations 
The formulations used for screening were 
test drug I (Amalaki + Haritaki), test drug II (Amalaki 
+ Bibhitaki), test drug III (Haritaki + Bibhitaki) and 
test drug IV (Amalaki + Haritaki + Bibhitaki), 
prepared as per the classical textual method of 
Charaka Samhita. The whole work were conducted in 
two sections viz. toxicity evaluation and experimental 
study at Institute of biomedical and industrial 
research & Bilwal medchem research laboratory pvt 
ltd, Reengus, Jaipur, Rajasthan, India. All the trials 
were carried out after obtaining permission from 
Institutional animal ethics committee and 
Institutional ethics committee. 
 [A] Toxicity evaluation 
Oral Acute Toxicity Study was done according 
to OECD guideline 423. 
i) Animals and husbandry conditions 
Healthy albino wistar rats (180-250 gm) of 
either sex were selected for the animal experiment 
and animals were maintained as per animal ethical 
committee regulations approved by the ‘Committee 
for the Purpose of Control and Supervision of 
Experiments on Animals’ (CPCSEA). They were 
acclimatized in the laboratory condition for two 
weeks prior to the experimentation. Animals had 
been group-caged on the bases of dose into group 1 
to group 8 successively, each group have 3 rats.  
ii) Preparation of animals 
The animals were randomly selected, marked 
with Picric acid H (Mark on head), B (Mark on Back), 
T (Mark on Tail) for individual identification, and 
kept in their cages for at least 5 days prior to dosing 
to allow for acclimatization to the laboratory 
conditions. 
iii) Number of animals and dose levels in toxicity 
study 
Three animals were used for each group. The 
dose level to be used as the starting dose was 
selected from one of two fixed levels 2000 mg/kg 
body weight in four groups and 5000 mg/kg body 
weight in another four groups. Total eight groups 
were selected. 
iv) Administration of doses 
For toxicity studies, the test substance was 
administered in a single dose by gavage using an oral 
feeding needle. Animals were fasted prior to dosing. 
Following the period of fasting, the animals weighed 
and the test substance administered. After the 
substance was administered, food was withheld for a 
further 3-4 hours in rats. All observations were 
systematically recorded. 
[B] Experimental study 
i) Animal grouping: 
36 healthy adult albino wistar rats weighing between 180-250 gm were selected randomly and divided 
in 6 groups. Each group has 6 animals, treated for 63 days as shown in table 1. 
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Table 1: Grouping of animals for experimental study 
Groups Details Day 1 Day 60 Day 63 
Evaluation 
parameters 
1.Normal 
Control 
CMC (Vehicle) was 
given in this group 
 
 
 
 
Blood 
sample 
collection 
from animals 
of all groups 
 
 
Blood sample 
collection from 
animals of all 
groups + 
Cyclophospham
ide (200 mg/kg, 
SC.) induced in 
animals of all 
groups 
 
 
 
 
Blood 
sample 
collection 
from animals 
of all groups 
 
 
 
 TLC number 
(cells/mm3) 
 % Neutrophil 
number 
 Serum 
immunoglobu
lin level (in 
ZST units) 
2.Standard 
Control 
Levamisole was given 
in this group 
3.Test 
drug I 
Therapeutic dose with 
vehicle was given 
4.Test 
drug II 
Therapeutic dose with 
vehicle was given 
5.Test 
drug III 
Therapeutic dose with 
vehicle was given 
6.Test 
drug IV 
Therapeutic dose with 
vehicle was given 
ii) Neutropenia causing (alkylating) agent 
Cyclophosphamide injection (Brand name: Cycloxan 200mg), Batch No. KB7131001, MFG.-OCT.2016, 
EXP.-SEP.2020, Manufactured in India by Biochem pharmaceuticals Industry, Mumbai. 
iii) Dose Fixation 
The dose of the drug was calculated by extrapolating the therapeutic dose of human to rat dose on the 
basis of surface area ratio by referring to the table of Paget and Barnes.[8] 
(a) Chaturthamalaka Rasayana as test drug 
Suggested human dose for Avaleha[9] = 10gm BD 
Rat dose = 10,000× 0.018×5 (Conversion factor).  
= 900mg/kg BD 
This dose was introduce in animals only after adding Dadhi in an equal quantity as same as, each of the other 
raw drugs taken in the formulation of Chaturthamalaka Rasayana, mentioned previously. 
(b) Cyclophosphamide = Single dose of 200 mg//kg[10] 
(c) Levamisole = 2.5mg/Kg [10] 
Levamisole is an antiparasitic drug that also has been found immunomodulatory activity by enhancing 
T-cell function and cellular immunity (increase TLC number). 
(d) Normal Control = 0.5% w/v CMC [Carboxymethylcellylose] solution, 1 ml/kg/day as a vehicle. 
iv) Route of Administration 
All the test drugs, vehicle and levamisole were administered orally with the help of oral feeding needle. 
Only Cyclophosphamide was given subcutaneously. 
v) Experimental study 
1) Cyclophosphamide induced neutropenia[10] 
The Cyclophosphamide induced neutropenia model concentrates on the effect of drugs on the 
haemopoetic system. If the test drug causes decrease in the Cyclophosphamide induced neutropenia suggesting 
that it attenuates the effect of Cyclophosphamide on the haemopoetic system. 
2) Effect on Serum immunoglobulin level by using zinc sulphate turbidity (ZST) test[10] 
The estimation of serum immunoglobulin levels was used to evaluate the increase in serum 
immunoglobulin production after the administration of the drugs. Immunoglobulins are antibodies that react 
specifically with the antigen. The zinc sulphate turbidity test is used to gain a rough estimation of the amount of 
Immuno-globulins present in the serum. Zinc sulphate causes precipitation of the Immunoglobulins making the 
solution cloudy. A lack of cloudiness signifies lack of immunoglobulins. The turbidity is expressed as ZST units, 
which in turn indicate the amount of immunoglobulin present in the sample. 
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vi) Evaluation of blood On day 1st , 60th and day 63rd  
a) Estimation of TLC (Total leucocyte count) number 
b) Estimation of neutrophils 
c) Estimation of immunoglobulin by zinc sulphate turbidity (ZST) test 
vii) Study protocol (Fig 1) 
First, the blood samples were collected on day 1, before administration of test drugs, from all the 
animals of all groups. Then the estimation of total leucocyte count (TLC) in cells/mm3, neutrophil count and 
serum immunoglobulin level (in ZST units) in the blood was done. In the previously prepared test drug, the 
Dadhi was added in a quantity calculated according to dose calculations. Then all four test drugs along with 
vehicle control and standard control were administered for 60 days continuously. On 60th day, six hours after 
the last dose, again blood was collected for the estimation of the same previous blood parameters as same as 
done on day 1. On the same day (60th day), neutropenic dose of Cyclophosphamide was injected in animals of 
all groups that depletes expending lymphocyte population and this day was labelled as day Zero.[11] On day 3 
(63rd day) after the injection of Cyclophosphamide, again blood was collected, for the estimation of the same 
previous blood parameters as same as done on day 1 and day 60. The serum was used for estimation of 
immunoglobulin levels using method devised by Mullen (1975).[12,13] Briefly, in this method, for each serum 
sample, a control tube containing 6 ml of distilled water and a test tube containing 6 ml of zinc sulphate 
solution was prepared. To each, 0.1 ml of serum was added from a pipette. They were inverted to enable 
complete mixing of the reagents and left to stand for 1 hr at room temperature. The first tube served as blank 
and the second tube was taken as sample. The turbidity developed was measured using a Digital 
Nepheloturbidity Meter. The turbidity obtained (sample-blank) was compared with that obtained with 
standard barium sulphate (BaSO4) solution. The standard BaSO4 solution was prepared by adding 3 ml of 
barium chloride solution (1.15% w/v) to 97 ml of 0.2 N sulphuric acids. The turbidity obtained with this 
solution was expressed as 20 zinc sulphate turbidity (ZST) units. The TLC, neutrophil counts (%) and serum 
immunoglobulin level of the blood in treated groups were compared with the values of the control group. 
Fig 1. Experimental work in animal laboratory 
   
Rats Caging System Dose Administration Blood Collection 
   
Equipment Oral Feeding Needle ZST Test Apparatus 
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viii) Statistical analysis 
The experimental results of immunomodulatory effect of all four test drugs on TLC, neutrophils and 
serum Immunoglobulin level in wistar rats blood were expressed as mean ± S.E.M. Data were analysed by 
ordinary one way analysis of variance (ANOVA) followed by Dunnett’s multiple comparison ‘t’ test using Graph 
pad Prism 7 software, with the level of significance set at P < 0.05 (at 95 % confidence interval). 
OBSERVATIONS AND RESULTS 
Toxicity study 
 Before starting actual experimental study, as per protocol, the toxicity study of all the four test samples 
was successfully done in animals. After administration of test drugs I, II, III, IV at dose 2000 mg/kg and 5000 
mg/kg, it was found safe. No any behavioural and haematological changes found observed in 14 days. 
Experimental Study 
 The results found in the animal study for four test drugs compared with control and standard drugs for 
63 days were given below in table no 2 and 3, with graph no.1 for TLC number, in table no. 4 and 5, with graph 
no.2 for % neutrophil number and in table no.6 and 7, with graph no.3 for serum immunoglobulin level (in ZST 
units), separately for each parameter, where NS = Non significant, */**/*** = Significant and **** = Highly 
significant. 
Table 2: Readings for TLC number (cells/mm3) 
Days 
Control Standard Test d. I Test d. II Test d. III Test d. IV 
Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM 
0 day 
5474.67 ± 
65.43 
5457.50 ± 
87.59 
5429.67 ± 
92.75 
5568.33 ± 
56.80 
5311.17 ± 
111.67 
5400.17 ± 
70.65 
60th 
day 
5423.00 ± 
71.62 
5555.33 ± 
96.40 
5471.83 ± 
136.16 
5560.67 ± 
62.67 
5672.00 ± 
81.65 
5758.50 ± 
60.83 
63rd 
day 
2442.50 ± 
67.12 
3282.00 ± 
76.71 
3029.17 ± 
42.08 
2736.17 ± 
49.58 
2749.83 ± 
52.73 
3136.8 ± 35.08 
 
Graph No.1: Readings for TLC number (cells/mm3) 
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Table 3: Readings for TLC number (cells/mm3) 
Dunnett's multiple 
comparisons test 
Mean Diff. 95.00% CI of diff. Summary Adjusted P Value 
0 Day 
Control vs. Standard 17.17 -262 to 296.3 NS 0.9997 
Control vs. Test I 45 -234.1 to 324.1 NS 0.9929 
Control vs. Test II -93.66 -372.8 to 185.5 NS 0.8599 
Control vs. Test III 163.5 -115.6 to 442.6 NS 0.4268 
Control vs. Test IV 74.5 -204.6 to 353.6 NS 0.9384 
60th day 
Control vs. Standard -132.3 -411.5 to 146.8 NS 0.6247 
Control vs. Test I -48.83 -328 to 230.3 NS 0.9896 
Control vs. Test II -137.7 -416.8 to 141.5 NS 0.5896 
Control vs. Test III -249 -528.1 to 30.15 NS 0.0965 
Control vs. Test IV -335.5 -614.6 to -56.35 * 0.0123 
63rd Day 
Control vs. Standard -839.5 -1119 to -560.4 **** 0.0001 
Control vs. Test I -586.7 -865.8 to -307.5 **** 0.0001 
Control vs. Test II -293.7 -572.8 to -14.52 * 0.0356 
Control vs. Test III -307.3 -586.5 to -28.18 * 0.0255 
Control vs. Test IV -694.3 -973.5 to -415.2 **** 0.0001 
Above table shows the data related to effect of all four test drugs along with standard and control drug 
on Total leucocyte count (TLC) in albino rats. After drug administration, on 60th day, it was found that only test 
drug IV increase the TLC level while others still remains same, with no better marginal differences. 
Administration of cyclophosphamide leads to the decrease in the count of TLC, especially neutrophils 
(neutropenia), confirms the reported myelosuppressive activity of the toxicant. After induction of neutropenia, 
on 63rd day, treatment with test drugs I and IV have highly significantly while test drug II and III have 
significantly maintain the TLC level when compared with standard drug. 
Table 4: Readings for % Neutrophil number 
Days 
Control Standard Test d. I Test d. II Test d. III Test d. IV 
Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM 
0 Day 14.34 ± 0.25 13.67 ± 0.22 14.03 ± 0.32 14.17 ± 0.26 14.04 ± 0.19 14.01 ± 0.24 
60th day 14.42 ± 0.25 13.58 ± 0.28 15.75 ± 0.40 14.29 ± 0.29 14.29 ± 0.19 14.17 ± 0.20 
63rd Day 6.43 ± 0.39 9.22 ± 0.30 8.00 ± 0.22 7.83 ± 0.19 7.91 ± 0.20 8.01 ± 0.44 
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Graph No.2: Readings for % Neutrophil number 
 
Table 5: Readings for % Neutrophil number 
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Summary Adjusted P Value 
0 Day 
Control vs. Standard 0.67 -0.3376 to 1.678 NS 0.3079 
Control vs. Test I 0.31 -0.6976 to 1.318 NS 0.8959 
Control vs. Test II 0.17 -0.8376 to 1.178 NS 0.9913 
Control vs. Test III 0.3 -0.7076 to 1.308 NS 0.9075 
Control vs. Test IV 0.33 -0.6776 to 1.338 NS 0.8708 
60th day 
Control vs. Standard 0.84 -0.1676 to 1.848 NS 0.1340 
Control vs. Test I -1.33 -2.338 to -0.3224 ** 0.0050 
Control vs. Test II 0.13 -0.8776 to 1.138 NS 0.9971 
Control vs. Test III 0.13 -0.8776 to 1.138 NS 0.9971 
Control vs. Test IV 0.25 -0.7576 to 1.258 NS 0.9537 
63rd Day 
Control vs. Standard -2.79 -3.798 to -1.782 **** 0.0001 
Control vs. Test I -1.57 -2.578 to -0.5624 *** 0.0007 
Control vs. Test II -1.4 -2.408 to -0.3924 ** 0.0028 
Control vs. Test III -1.48 -2.488 to -0.4724 ** 0.0014 
Control vs. Test IV -1.58 -2.588 to -0.5724 *** 0.0006 
Above table shows the data related to effect of all four test drugs along with standard and control drug 
on neutrophil count in albino rats. After drug administration, on 60th day, it was found that only test drug I 
increases the neutrophil count while others still remains same, with no better marginal differences. After 
induction of neutropenia, on 63rd day, treatment with all the test drugs have significantly maintain the level of 
neutrophil count when compared with standard drug. 
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Table 6: Reading for Serum immunoglobulin level (in ZST units) 
Days 
Control Standard Test I Test II Test III Test IV 
Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM 
0 Day 28.94 ± 0.50 28.84 ± 0.44 28.27 ± 0.55 28.60 ± 0.35 28.96 ± 0.43 28.87 ± 0.45 
60th day 28.68 ± 0.46 28.47 ± 0.36 29.52 ± 0.45 28.91 ± 0.53 28.80 ± 0.42 28.57 ± 0.52 
63rd Day 16.00 ± 0.39 23.29 ± 0.48 18.38 ± 0.78 17.86 ± 0.46 17.62 ± 0.55 19.71 ± 0.28 
Graph No.3: Reading for Serum immunoglobulin level (in ZST units) 
 
Table 7: Reading for Serum immunoglobulin level (in ZST units) 
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Summary Adjusted P Value 
0 Day 
Control vs. Standard 0.1 -1.629 to 1.829 NS 0.9998 
Control vs. Test I 0.67 -1.059 to 2.399 NS 0.7797 
Control vs. Test II 0.34 -1.389 to 2.069 NS 0.9824 
Control vs. Test III -0.02 -1.749 to 1.709 NS 0.9999 
Control vs. Test IV 0.07 -1.659 to 1.799 NS 0.9999 
60th day 
Control vs. Standard 0.21 -1.519 to 1.939 NS 0.9980 
Control vs. Test I -0.84 -2.569 to 0.8892 NS 0.6033 
Control vs. Test II -0.23 -1.959 to 1.499 NS 0.9966 
Control vs. Test III -0.12 -1.849 to 1.609 NS 0.9997 
Control vs. Test IV 0.11 -1.619 to 1.839 NS 0.9997 
63rd Day 
Control vs. Standard -7.29 -9.019 to -5.561 **** 0.0001 
Control vs. Test I -2.38 -4.109 to -0.6508 ** 0.0031 
Control vs. Test II -1.86 -3.589 to -0.1308 * 0.0303 
Control vs. Test III -1.62 -3.349 to 0.1092 NS 0.0741 
Control vs. Test IV -3.71 -5.439 to -1.981 **** 0.0001 
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Above table shows the data related to effect of all four test drugs along with standard and control drug 
on serum immunoglobulin level in albino rats. After drug administration, on 60th day, it was found that none of 
the four test drug increases the serum immunoglobulin level, with better marginal differences as compared to 
standard drug. After induction of neutropenia, on 63rd day, treatment with test drug IV have highly significantly, 
test drugs I and II have significantly maintain the serum immunoglobulin level while test drug III have not 
maintain the level, with better marginal differences, as compared with standard drug. 
DISCUSSION 
[A] Toxicity Study 
The alternate combinations of Amalaki, Haritaki and Bibhitaki in Chaturthamalaka Rasayana were 
found totally safe in experimental animals. None of the ingredients of the test drug has reported any toxicity. 
Further acute and chronic toxicity studies conducted on this basic drugs itself proves their safety profile as 
well.[14-19] Also all four test drugs were just a classical formulations made by logical thinking of great ancient 
experts. That’s why prediction of not finding the chances of toxicity was absolutely proven true. 
[B] Experimental Study 
 In animal experimental study, the results found were so encouraging to take the Chaturthamalaka 
Rasayana in a further clinical study. For more elaboration, the obtained pharmacological profile has been given 
in the form of final consolidated statement in table 8. 
Table 8: Consolidated statement of effect of test formulations on parameters 
Test Drug TLC number (cells/mm3) % Neutrophil number 
Serum immunoglobulin (ZST 
units) 
 0 Day 
60th 
Day 
63rd 
Day 
0 Day 
60th 
Day 
63rd 
Day 
0 
Day 
60th 
Day 
63rd 
Day 
I NS NS **** NS ** *** NS NS ** 
II NS NS * NS NS ** NS NS * 
III NS NS * NS NS ** NS NS NS 
IV NS * **** NS NS *** NS NS **** 
NS = Non Significant,  */**/***= Significant, ****= Highly Significant 
i) Effect on TLC number (cells/mm3) 
On 60th day, only the test drug IV shows significant results and another sample had non-significant 
response. While after administration of immunosuppressant (Cyclophosphamide) and tests drugs for 3 days, it 
was found that all test drugs I, II, III, IV shows statistically significant changes in number of TLC. Test drug IV 
and after that test drug I had found similar response in comparison of standard group. 
ii) Effect on % Neutrophil number 
On 60th day, evaluation of immunomodulatory response on healthy wistar rats after oral administration 
of 900 mg/kg and observed neutrophils count was found that, test drug I had significant changes (p=0.0050). 
After administration of cyclophosphamide, on 63rd day, all the test drugs shows positive changes but found 
statistically less significant in comparison of standard. 
iii) Effect on Serum immunoglobulin 
On 60th day, evaluation of immunomodulatory response on healthy wistar rats after oral administration 
of 900 mg/kg and observed serum immunoglobulin level was found no any statically significant changes for all 
test drugs. After administration of immunosuppressant (Cyclophosphamide) and administration of tests 
samples for 3 days was found that, test drug IV had found similar response in comparison of standard group 
(p=0.0001). 
[C] Probable mode of action of drug 
A drug (Dravya) performs certain actions (Karma) in the body by virtue of its properties i.e. Guna 
(property), Rasa (taste), Virya (potency), Vipaka (metabolism) and Prabhava (exceptional activity) which exist 
in it in a state of co-inherence i.e. Rasapanchaka (table 9). Equality of proto-elements of the drug on one hand 
and the proto-elemental constituents of the body on the other hand forms on the basis of the Samanya - 
Vishesha Siddhanta (principles). These principles indicate that the leading proto-elements of the drug will 
increase similar proto-elements in the body and the dissimilar will decrease the proto-elements. The actions of 
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a drug are closely linked to its chemical structure in the form of a preponderance of one or two proto-elements 
presents to them. 
Table 9: Rasapanchaka of contents of Chaturthamalaka Rasayana 
S. No. Dravya Rasa Vipaka Virya Guna Karma/Prabhava 
1. Amalaki 
Pancharasa 
(Lavana Varjita) 
Madhura Shita 
Guru, 
Ruksha 
Rasayana [20] 
2. Haritaki 
Pancharasa 
(Lavana Varjita) 
Madhura Ushna 
Laghu, 
Ruksha 
Rasayana [21] 
3. Bibhitaki Kashaya Madhura Ushna 
Laghu, 
Ruksha 
Netrya, Keshya, 
Vaisvaryanashana [22] 
4. Dadhi Amla, Kashaya Amla Ushna 
Guru, 
Snigdha 
Dipana, Hridya, Pushtikrita 
[23] 
5. Madhu Madhura, Kashaya Katu Shita 
Laghu, 
Ruksha 
Yogavahi, Chedana, Lekhana 
[24] 
6. Ghrita Madhura Madhura Shita 
Guru, 
Snigdha 
Rasayana, Dipana, Netrya 
[25] 
7. Tila 
Katu, Tikta, 
Madhura, Kashaya 
Katu Ushna 
Guru, 
Snigdha 
Balya, Keshya, 
Agnivardhaka, Medhya [26] 
8. 
Tila 
Tailam 
Madhura, Kashaya, 
Tikta 
Madhura Ushna 
Guru, 
Snigdha 
Bala Varnakaraka, Vrishya, 
Dipana [27] 
9. Sharkara Madhura Madhura Shita 
Laghu, 
Snigdha 
Brihana, Vata-Rakta Pitta-
Daha Shamana, Netrya [28] 
The Rasayana Dravyas, mostly those with 
Madhura Vipaka are advocated as ‘adaptogen’ in 
Ayurveda, primarily activate immune cells, leading to 
secretion of cytokines, which in turn act on multiple 
target organs. It has been found that the nervous, 
endocrine and immune systems are all interrelated. 
Immune products like various cytokines have been 
found to stimulate the hypothalamus-pituitary-
adrenal axis and corticotrophin release factor (CRF), 
which ultimately enhances the production of adrenal 
corticotropic hormone (ACTH) resulting into 
increased secretion of glucocorticoids which have an 
overall suppressive effect on the immune system. 
Stress, anxiety and immunosuppression also act on 
the same axis and bring about changes in the immune 
status of the body. These Rasayana Dravya probably 
pretend to reduce stress levels of both body and 
mind. So these Rasayana Dravya act as a potent 
immunomodulator to keep health of a consumer. 
In most human diseases, the oxidative stress 
is the secondary phenomena, for e.g., activated 
neutrophils produce O2-, H2O2 and HOCl to kill 
phagogens. If a large number of phagocytes become 
activated in a localized area they can produce tissue 
damage. e.g., synovial fluid in sole and knee joints of 
rheumatoid arthritis contains large number of 
activated neutrophils. Some human diseases may be 
due to oxidative stress. e.g., excess radiation to 
biological system causes free radical damage to 
protein, DNA and lipids. Neurological disorders by 
dietary difference of tocopherol are mediative by 
oxidative stress. It also produces intracellular free 
Ca2+ damage to membrane ion transporters and 
other specific protein and peroxidation of lipids. 
Hence, to protect from damage cells produce 
enzymes, or by intake of free radical scavenger 
substances to neutralizing or detoxify the free 
radical, known as antioxidant. Thus, the imbalance 
between free radical and anti-oxidant resulting 
diseases. In biological systems two types of 
antioxidants are proven useful against pathogenesis. 
Endogenous antioxidant and exogenous antioxidant. 
Chaturthamalaka Rasayana seems to be contained 
both types. The immune system has connections with 
a number of other organs and can directly or 
indirectly affect the actions of these organs. The 
function of the immune system is the protection of 
our bodies against foreign invaders. It plays a pivotal 
role in the pathogenesis of immune deficient 
diseases, autoimmunity and allergy. Ayurveda has 
great faith in pure treatment which cures the disease 
as well as provides physical, mental and social health 
too. Rasayana are health encouraging and 
rejuvenating agents which by their empirical effects 
produce resistance against disease both physically 
and mentally. Both lymphocytes and neutrophils 
were significantly increased by Rasayana Chikitsa. 
Chaturthamalaka Rasayana accelerated the recovery 
of the haemopoietic system by a rapid rise in total 
leukocytes. To induce neutropenia, we used 
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cyclophosphamide, a drug used in cancer treatment. 
It suggests that, the Chaturthamalaka Rasayana 
might be shows significant results in cancer patients. 
CONCLUSION 
The results of this experimental work are 
very encouraging & indicate that Triphala should be 
studied more extensively to confirm & reveal other 
potential therapeutic effects also. In toxicity study, all 
the test drugs I, II, III and IV under Chaturthamalaka 
Rasayana were discovered safe in acute dose upto 
5000 mg/kg in albino rats. All the four test drugs 
were found effective in immunosuppressive rat 
model. Over all, Chaturthamalaka Rasayana is having 
significant cytoprotective activity and moderate 
immunostimulant activity. Among them, test drug IV 
containing Triphala found more potent, as similar as 
the standard group (Levamisole) having better 
activity profile in terms of both cytoprotective as well 
as immunostimulant activity. Chaturthamalaka 
Rasayana might be used as a cost effective and 
adulteration free Rasayana drug to overcome the use 
of Chyavanprasha Avaleha, which has issues of cost 
and adulteration. Chaturthamalaka Rasayana might 
be considered as an immunity booster drug in an 
adjuvant therapy. For this purpose, more clinical 
trials needed. 
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